New Milford, CT, United States of America

Sabine K Schlyer

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Boehringer Ingelheim International Gmbh, Aerie Pharmaceuticals, Inc.. Active years: 2012-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sabine K Schlyer. Retrieved from https://idiyas.com/inventor/sabine-k-schlyer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 7.7

ph-index = 2

Forward Citations = 46(Granted Patents)

Company Filing History:

6 out of 1,562

Boehringer Ingelheim International Gmbh

patents

2 out of 60

Aerie Pharmaceuticals, Inc.

patents

Years Active: 2012-2020

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10624882 - Rho kinase inhibitors (2020-04-21),

2. 8815857 - Soluble guanylate cyclase activators (2014-08-26),

3. 8809326 - Isoquinolinone Rho kinase inhibitors (2014-08-19),

4. 8697911 - Rho kinase inhibitors (2014-04-15),

5. 8637550 - Heteroaryl diamide compounds useful as MMP-13 inhibitors (2014-01-28),

6. 8450317 - CXCR3 receptor antagonists (2013-05-28),

7. 8362249 - CXCR3 receptor antagonists (2013-01-29),

8. 8338367 - Fused heteroaryl diamide compounds useful as MMP-13 inhibitors (2012-12-25),

Title: The Innovative Contributions of Sabine K Schlyer

Introduction

Sabine K Schlyer is a prominent inventor based in New Milford, CT, known for her significant contributions to the field of pharmaceuticals. With a total of eight patents to her name, she has made remarkable strides in developing novel compounds that address various medical conditions.

Latest Patents

Among her latest patents are Rho kinase inhibitors, which disclose novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives. These compounds are useful as inhibitors of Rho kinase and are aimed at treating a variety of diseases and disorders mediated by Rho kinase activity, including cardiovascular diseases. Additionally, her patent on soluble guanylate cyclase activators relates to specific compounds and their pharmaceutical compositions, methods of use, and processes for preparation.

Career Highlights

Sabine has worked with notable companies such as Boehringer Ingelheim International GmbH and Aerie Pharmaceuticals, Inc. Her work in these organizations has allowed her to contribute to the advancement of pharmaceutical research and development.

Collaborations

Throughout her career, Sabine has collaborated with esteemed colleagues, including John David Ginn and Anthony S Prokopowicz. These partnerships have further enhanced her innovative efforts in the pharmaceutical industry.

Conclusion

Sabine K Schlyer exemplifies the spirit of innovation in the pharmaceutical field through her patents and collaborations. Her work continues to impact the treatment of various diseases, showcasing her dedication to advancing medical science.

Profile summary based on public USPTO records.